Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Attendo AB (publ) – The Nomination Committee’s proposal prior to the AGM 2017

The Nomination Committee of Attendo AB (publ) proposes re-election of the board members Ulf Lundahl, Mona Boström, Catarina Fagerholm, Tobias Lönnevall, Anssi Soila, Anitra Steen, and Henrik Borelius (CEO). Chairman of the Board Erik Lautmann and board member Jan Frykhammar has informed that they are not available for re-election. The Nomination Committee proposes that Ulf Lundahl is elected as new Chairman of the Board. For information about the Nomination Committee’s proposal for Board of Directors, fees to the Board of Directors, and auditor as well as the statement on the proposed

Infranode closes SEK 1.9 Bn second investment round reaching SEK 3.35 Bn total

– First private infrastructure investment platform in the Nordics to receive funding from the European Fund for Strategic investments (EFSI) Infranode is pleased to announce the closing of its second investment round. The Infranode I investment platform raises SEK 1.9 Bn dedicated to essential infrastructure investments in the Nordics. It brings the total capital raised to date to SEK 3.35 Bn. The investors are e.g. Folksam, KPA Pension, the European Investment Bank (EIB) and IMAS Foundation. “We are very proud to get such strong support from institutional investors as the EIB,

Completion of sale of Nordic Waterproofing Holding A/S shares

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, SWITZERLAND, SOUTH AFRICA, SINGAPORE, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFULFunds advised by Axcel Management A/S (“Axcel”) and KIRKBI Invest A/S (“KIRKBI”) have sold 3,400,422 and 599,772 shares respectively in Nordic Waterproofing Holding A/S (“Nordic Waterproofing”) through an accelerated bookbuilding to Swedish and international institutional investors at a price of SEK 90.00 per share (“the

Year-end Bulletin 2016

“We continue to build a new global leader in the field of patient monitoring”Significant events during the first quarter · March 2016. Senzime has been appointed one of ten leading medical technology companies by the CEBR - Council for European bioregions. Significant events during the second quarter · April 2016. Senzime receives research grant from Vinnova through BIO-X to conduct a study designed for clinical evaluation of OnZurf Probe and CliniSenz Analyzer for postoperative monitoring of patients with esophageal cancer. The grant amounts to SEK 2 million, and the study

is planning to carry out a fully underwritten rights issue for further market launches and is taking steps toward listing at Nasdaq First North

Uppsala February 16, 2017. The Board of Senzime AB (publ) proposes that an extra general meeting resolves on a rights issue of approximately SEK 24.4 million before issue costs. The rights issue is fully underwritten by the company's principal owner. The proceeds will be used to enable the commercialization of Senzimes products and strengthen its financial position. Concurrently Senzime is planning a listing at Nasdaq First North.Summary of terms and relevant dates • Senzime’s board proposes a rights issue of approximately SEK 24.4 million. • The rights issue comprises up to 4,521,581

Sobi™ publishes its report for the fourth quarter and full year 2016

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the fourth quarter and full year 2016. Revenues for the full year totalled SEK 5,204 M, an increase of 61 per cent compared to 2015. Revenues for the quarter were SEK 1,292, an increase of 59 per cent. Product sales for the full year amounted to SEK 4,548 M, an increase of 77 per cent, based on strong performance across the portfolio and the launch of our new haemophilia products, Elocta® and Alprolix®. Business highlights Q4 2016 · European Commission approved the transfer of the

Revenio Group Corporation: Financial Statement Bulletin January 1-December 31, 2016

Revenio Group Corporation, Financial Statement Release, February 16, 2017 at 9:00 Revenio Group Corporation's Financial Statement Bulletin January 1-December 31, 2016 (Unaudited) This release is a summary of Revenio Group's January-December 2016 financial statement bulletin. The complete report is attached to this release as a pdf-file. The stock exchange release is also available on the company's website at www.revenio.fi. Q4/2016: Continued strong growth and profitability. Net sales +21%, operating profit +74% October-December 2016 in brief, continuing Group functions: ·

Konecranes Plc: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10

Konecranes has on February 15, 2017 received a notification under Chapter 9, Section 5 of the Securities Market Act, according to which the holding of Terex Corporation in Konecranes Plc’s shares and votes has fallen below 15 percent.Total positions of Terex Corporation on February 15, 2017:     % of % of shares Total of Total number of shares shares and voting both in % and voting rights of and rights (A+B) issuer voting through rights financial (

Viking Line Abp's Year-End report January - December 2016

Viking Line Abp               FINANCIAL STATEMENT RELEASE             16.2.2017, 9.00 AMVIKING LINE ABP'S YEAR-END REPORT JANUARY - DECEMBER 2016Consolidated sales of the Viking Line Group during the financial year, January 1 – December 31, 2016 was 519.6 million euros (EUR 530.5 M during January 1 – December 31, 2015). Other operating revenue amounted to EUR 2.0 M (0.5). Operating income totalled EUR 13.7 M (26.4). Net financial items totalled EUR -4.1 M (-3.2). Consolidated income before taxes amounted to EUR 9.6 M (23.2). Income after taxes totalled EUR 8.0 M (18.7).The Board of

Kuehne + Nagel ordering 326 trolleys from FlexQube

Logistic company Kuehne + Nagel orders 326 trolleys for the use of one of their clients where they will take over the logistics process. Kuehne + Nagel will use the trolleys with Liftrunners transport solution from STILL GmbH which FlexQube has an official partnership with.Anders Fogelberg, CEO of FlexQube, comments: "This is the first major transaction we undertake together with STILL GmbH after we signed our agreement for the distribution and sale for them in September 2016. FlexQube already has a few thousand wagons in operation of different customers with the Liftrunner transport

Year-end report 2016 and quarterly report October – December 2016

Quote from Per Eriksson, President and CEO- ”2016 was another exciting year for NetEnt with new record levels in revenues, earnings and cash flow. The fourth quarter developed well – revenues increased by 23.9 percent and the operating margin improved to 39.0 percent. Great Britain continues to offer great growth potential for us and in December, it became our largest geographical market for the first time. Looking ahead in 2017, we see conditions for continued solid growth, supported by a strong pipeline of new games, UK, mobile, new customers to launch as well as our expansion in North

Munksjö Oyj’s Financial Statements Bulletin 2016: Profitability target of 12% reached, record high full-year results and cash flow

MUNKSJÖ OYJ, FINANCIAL STATEMENTS BULLETIN, Helsinki, Finland, 16 February 2017 at 07:30 AM CET Munksjö Oyj’s Financial Statements Bulletin 2016: Profitability target of 12% reached, record high full-year results and cash flow Highlights of the fourth quarter 2016 ·  Net sales were EUR 282.4 (290.0) million. ·  Adjusted EBITDA was EUR 36.1 (22.1) million and the adjusted EBITDA margin was 12.8% (7.6%). Items affecting comparability (IAC) amounted to EUR -6.6 (0.0) million, mainly related to the planned combination.  ·  Operating result was EUR 16.4 (8.5) million and net

The Nomination Committee’s proposal to the Board of Directors in Kungsleden AB (publ)

The Nomination Committee at Kungsleden AB (publ) is proposing the election of Ingalill Berglund as a new member of the Board of Directors at the Annual General Meeting (AGM) 2017. The Nomination Committee also proposes that current members of the Board - Charlotte Axelsson, Joachim Gahm, Liselotte Hjorth, Göran Larsson, Kia Orback Pettersson and Charlotta Wikström are re-elected to the Board of Directors. It is further proposed that Göran Larsson is re-elected as Chairman of the Board of Directors. Ingalill Berglund has over 20 years of experience in the real estate industry and was CEO of

Year-end report 1 January – 31 December 2016

3 months ended 31 December 2016 · Local currency sales increased by 8% and Euro sales increased by 5% to €355.1m (€339.5m). · Number of registered actives* decreased by 7% to 3.0m. · EBITDA amounted to €49.0m (€39.7m). · Operating margin was 11.8% (9.6%, adjusted** 11.5%), impacted by -110 bps from currencies, and operating profit was €42.0m (€32.6m, adjusted** €38.9m). The operating margin was favourably impacted by a VAT income related to the Russian tax case, fully offset by Ukrainian and other one-off restructuring costs as well as costs linked to the outsourcing of

Qt Group Plc updates its strategy and long-term goals and is planning to seek additional funding via rights issue

QT GROUP PLCSTOCK EXCHANGE RELEASEFEBRUARY 16, 2017The Board of Directors of Qt Group Plc have updated the company strategy for the years 2017-2021. In accordance with the updated strategy, the company is announcing its new long-term financial goals to achieve in 2021 an annual turnover of 100 million euros with more than 15 percent operating profit margin (EBIT%). The updated strategy is based on strong investment in growth, focusing mainly on increasing Qt's market share among major device vendors as the preferred solution for touch screen-based technology software development. To

QT GROUP PLC FINANCIAL REPORTING 2017

QT GROUP PLC STOCK EXCHANGE RELEASE 16.2.2017 AT 08:00Segment reporting Qt Group comprises of one reportable segment that offers software development tools to its customers. The chief operating decision maker of Qt Group is the CEO together with the Group’s management team. Due to the business model of Qt Group and the nature of its operations and governance structure, Qt Group forms one reportable operating segment, Qt Group. The figures of the reportable segment form the figures of Qt Group. Revenue from products and services Qt Group has previously reported its revenue as one

NOTICE TO THE ANNUAL GENERAL MEETING OF QT GROUP PLC

QT GROUP PLCSTOCK EXCHANGE RELEASEFEBRUARY 16, 2017Notice is given to the shareholders of Qt Group Plc (“company”) to the Annual General Meeting to be held on Tuesday, March 14, 2017, starting at 10.00 a.m. at Kansallissali, address Aleksanterinkatu 44 A, 2nd floor, 00100 Helsinki, Finland. The reception of persons who have registered for the meeting and distribution of voting tickets will commence at 9:00 a.m. A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING At the Annual General Meeting the following matters will be considered: 1. Opening of the meeting 2. Calling

Targovax ASA: Fourth quarter and full year 2016 results

Oslo, Norway, 16 February 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below). Highlights: · Targovax was granted a European Patent for the ONCOS platform lead product, ONCOS-102, extending patent coverage following the award of a similar US patent in June.

Diös Fastigheter Year-end report 2016

Diös Fastigheter reported its strongest result to date and major new acquisitions creates new opportunities. The Board proposes a 26 per cent increase in the dividend.·Rental income for the period amounted to SEK 1 323 million (1 295) ·Property management income amounted to SEK 539 million (508) ·Unrealized changes in property values amounted to SEK 337 million (262) and for derivatives to SEK 91 million (64) ·Profit after tax was SEK 832 million (542) ·Earnings per share without regards to the rights issue were SEK 11.04 (7.09) ·Earnings per share with

Strong leasing and value-creating projects

THE REPORT IN BRIEF The Year in Brief · New leasing amounted to SEK 216 (133) million and net leasing to SEK 99 (7) million. SEK 89 million of lease agreements were renegotiated, which resulted in increased average rental values of 8.8 per cent. · Rental revenues increased to SEK 2,422 (2,238) million and operating increased to SEK 1,602 (1,545) million. · The profit from property management increased by 5 per cent to SEK 990 (942) million. · Positive changes in the value of the property portfolio amounted to SEK 1,658 (970) million, following reduced yield requirements and

Pandox AB (publ) year-end report January – December 2016

Strong end to a strong yearQuarter October– December 2016 · Revenue from Property Management amounted to MSEK 458 (365). Adjusted for currency effects and comparable units, the increase was 6 percent. · Net operating income from Property Management amounted to MSEK 368 (306). Adjusted for currency effects and comparable units, the increase was 2 percent. · Net operating income from Operator Activities amounted to MSEK 130 (104). Adjusted for currency effects and comparable units, the increase was 10 percent. · EBITDA amounted to MSEK 464 (381). · Profit for the period

Full year report 2016

“Results from our Phase 3 study of CAM2038 in opioid dependence demonstrated significantly better treatment effect with our long-acting depots versus standard of care with daily sublingual tablets.”Business highlights fourth quarter 2016  · Positive pivotal phase 3 trial results received for long-acting buprenorphine, CAM2038, for treatment of opioid addiction. · Start of Phase 1-trial of CAM2047, CAM2038 and CAM2058 for treatment of nausea and pain. · Stage 1 of the establishment of Camurus´ European commercial organization and operational structure completed. · Expansion of

QT GROUP PLC FINANCIAL STATEMENTS BULLETIN 1 JANUARY 2016–31 DECEMBER 2016

Qt Group Plc’s fourth quarter 2016  STRONG GROWTH IN THE GLOBAL MARKET CONTINUEDFinancial year 2016:- Net sales EUR 32,395 thousand (EUR 26,934 thousand): up 20.3 per cent- Comparable operating profit was EUR 291 (1,922) thousand, comparable operating margin (EBIT %) was 0.9 per cent (7.1).- The comparable operating profit for 2015 included restructuring costs totalling EUR 136 thousand, while the comparable operating profit for 2016 includes non-recurring costs totalling EUR 2,026 thousand arising from the write-down of a loan receivable associated with the financing of the Qt

There are no items matching the current filter
There are no more items matching the current filter
Back to top